Novel Phage Lysin Abp013 against Acinetobacter baumannii
1
Antimicrobial Resistance Interdisciplinary Research Group, Singapore-MIT Alliance for Research and Technology Centre, Singapore 138602, Singapore
2
School of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore
3
Singapore Centre for Environmental Life Sciences Engineering, School of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore
4
The Ithree Institute, University of Technology Sydney, Sydney, NSW 2007, Australia
*
Authors to whom correspondence should be addressed.
Academic Editors: Hongping Wei and Carlos M. Franco
Antibiotics 2022, 11(2), 169; https://doi.org/10.3390/antibiotics11020169
Received: 9 December 2021
/
Revised: 11 January 2022
/
Accepted: 25 January 2022
/
Published: 28 January 2022
(This article belongs to the Special Issue Bacteriophage Lysins in the Era of Antibiotic Resistance)
As antimicrobial resistance (AMR) continues to pose an ever-growing global health threat, propelling us into a post-antibiotic era, novel alternative therapeutic agents are urgently required. Lysins are bacteriophage-encoded peptidoglycan hydrolases that display great potential as a novel class of antimicrobials for therapeutics. While lysins against Gram-positive bacteria are highly effective when applied exogenously, it is challenging for lysins to access and cleave the peptidoglycan of Gram-negative bacteria due to their outer membrane. In this study, we identify a novel phage lysin Abp013 against Acinetobacter baumannii. Abp013 exhibited significant lytic activity against multidrug-resistant strains of A. baumannii. Notably, we found that Abp013 was able to tolerate the presence of human serum by up to 10%. Using confocal microscopy and LIVE/DEAD staining, we show that Abp013 can access and kill the bacterial cells residing in the biofilm. These results highlight the intrinsic bacteriolytic property of Abp013, suggesting the promising use of Abp013 as a novel therapeutic agent.
View Full-Text
Keywords:
phage lysin; endolysin; multidrug resistance; Acinetobacter baumannii; novel antibacterial agent
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
- Supplementary File 1:
ZIP-Document (ZIP, 695 KiB)
MDPI and ACS Style
Chu, J.J.K.; Poh, W.H.; Hasnuddin, N.T.B.; Hew, E.Y.; Dam, L.C.; Sahili, A.E.; Rice, S.A.; Goh, B.C. Novel Phage Lysin Abp013 against Acinetobacter baumannii. Antibiotics 2022, 11, 169. https://doi.org/10.3390/antibiotics11020169
AMA Style
Chu JJK, Poh WH, Hasnuddin NTB, Hew EY, Dam LC, Sahili AE, Rice SA, Goh BC. Novel Phage Lysin Abp013 against Acinetobacter baumannii. Antibiotics. 2022; 11(2):169. https://doi.org/10.3390/antibiotics11020169
Chicago/Turabian StyleChu, Joash J.K., Wee H. Poh, Nabilah T.B. Hasnuddin, En Y. Hew, Linh C. Dam, Abbas E. Sahili, Scott A. Rice, and Boon C. Goh. 2022. "Novel Phage Lysin Abp013 against Acinetobacter baumannii" Antibiotics 11, no. 2: 169. https://doi.org/10.3390/antibiotics11020169
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
